Inspire Medical Systems Inc. (INSP) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-02, Inspire Medical Systems Inc. (NYSE: INSP) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $68.10 (-4.33% 1D, market cap $2.06B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, INSP ranks #119 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), INSP carries a Roarable C+ (66/100 RQD), trailing P/E of 14.2x, gross margin of 85.4%, and ROIC of 6.0%. By comparison, LMAT (LeMaitre Vascular Inc.) holds a C+ grade (69/100 RQD, P/E 33.8x, ROIC 14.7%, cap $1.95B) and XRAY (DENTSPLY SIRONA Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.92B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).
Per INSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001609550), Inspire Medical Systems Inc. generated $912.0M in revenue (+13.6% YoY), $145.4M in net income, and $78.5M in free cash flow against $907.3M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 11.40 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)
Capital intensity & 5.6% operating margin leave 12 pts on the table
Even with a 66/100 (C+) score, INSP faces multiple-compression risk if 14.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 82.9% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($68.77) or 200D SMA ($58.45) invalidates the momentum regime and cuts Target Base ($70.55) toward Bear Floor ($55.03).
Inspire Medical Systems Inc. (INSP) dropped -4.33% to $68.10, trading at 27% of its 52-week range ($38.91 – $147.03). Solid 85% profit margin (6% return on capital), mixed timing at 14x P/E—hold if owned, no rush to chase.
Yahoo Finance report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
For questions about this article or underlying research, email help@trefis.com.
Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results tomorrow after market close. Here’s what you need to know.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +13.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INSP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INSP. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Inspire Medical Systems Inc. (INSP) ranks #119 by composite RQD confidence (66/100, grade C+) and #256 by equity capitalization ($2.06B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. UFPT currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with INSP at 66/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INSP
ACTIVE
Inspire Medical Systems Inc. | C+ | 66/100 | 14.2x | 85.4% | 6.0% | -4.33% | $2.06B | Benchmark Subject |
| LMAT LeMaitre Vascular Inc. | C+ | 69/100 | 33.8x | 71.5% | 14.7% | -5.08% | $1.95B | /lmat-vs-insp → |
| XRAY DENTSPLY SIRONA Inc. | E | 32/100 | — | 50.0% | -11.0% | -0.83% | $1.92B | /xray-vs-insp → |
| UFPT UFP Technologies Inc. | B+ | 77/100 | 33.3x | 28.3% | 13.9% | -3.00% | $2.27B | /ufpt-vs-insp → |
| KMTS Kestra Medical Technologies Ltd. | D | 50/100 | — | 51.4% | -35.0% | -3.01% | $1.82B | /kmts-vs-insp → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Inspire Medical Systems Inc. (INSP) reported GAAP revenue of $912.0M (+13.6% vs. FY2024 revenue of $802.8M , and +46.0% cumulative change since FY2023) , GAAP net income of $145.4M, operating cash flow of $117.0M, and free cash flow of $78.5M (-13.9% YoY). On the balance sheet, INSP closed FY2025 with $907.3M in total assets against $0 in total debt (Altman Z-Score: 11.40, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $912.0M | $145.4M | $117.0M | $78.5M | $907.3M | — |
| FY2024 (FY) | 2024-12-31 | $802.8M | $53.5M | $130.2M | $91.1M | $808.4M | — |
| FY2023 (FY) | 2023-12-31 | $624.8M | -$21.2M | $24.7M | $24.7M | — | — |
As of 2026-11-02, Inspire Medical Systems Inc. (NYSE: INSP) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $68.10 (-4.33% 1D, market cap $2.06B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, INSP ranks #119 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), INSP carries a Roarable C+ (66/100 RQD), trailing P/E of 14.2x, gross margin of 85.4%, and ROIC of 6.0%. By comparison, LMAT (LeMaitre Vascular Inc.) holds a C+ grade (69/100 RQD, P/E 33.8x, ROIC 14.7%, cap $1.95B) and XRAY (DENTSPLY SIRONA Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.92B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).
Per INSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001609550), Inspire Medical Systems Inc. generated $912.0M in revenue (+13.6% YoY), $145.4M in net income, and $78.5M in free cash flow against $907.3M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
INSP last traded at $68.10 (-4.33% on volume of 796,443 shares), positioning the stock -0.97% below its 50-day simple moving average ($68.77) and +16.51% above its 200-day simple moving average ($58.45). Across its 52-week range of $38.91 to $147.03, INSP sits at the 27.0% percentile with a 14-day RSI of 53.5 (NEUTRAL RANGE) and an implied next-earnings move of ±7.6% ($62.92 to $73.28).
Why INSP Stock dropped -4.33% Today — RQD Quant Desk Flash. Solid 85% profit margin (6% return on capital), mixed timing at 14x P/E—hold if owned, no rush to chase.
Per the Roarable RQD rating, INSP scores 66 out of 100, a C+ grade with the verdict "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are:
For a prospective investor, the pattern is a balance sheet and insider signal that screen well against a cash-generation profile that screens weakly. Upside drivers implied by the data are the strong forensic balance sheet and the upper-half insider and flow readings. The valuation tradeoff is that trailing P/E of 14.2 sits alongside EV/EBITDA of 23.3 and a 6% ROIC, so earnings multiples and enterprise-level multiples tell different stories. The rating itself describes a hold-with-watch posture rather than a directional call.
Inspire Medical Systems Inc. is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry. Per the company profile, it operates as a publicly traded medical instruments company. Not available in source data: product descriptions, customer segments, and revenue model specifics beyond sector and industry classification.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $912.0M | $51.0M | $145.4M | N/A | $78.5M | $104.8M | N/A |
| FY 2024 | $802.8M | $36.1M | $53.5M | N/A | $91.1M | $150.2M | N/A |
| FY 2023 | $624.8M | $-40.3M | $-21.2M | N/A | $24.7M | N/A | N/A |
Per the SEC financials, revenue grew from $624.8M in FY 2023 to $912.0M in FY 2025, and operating income moved from a loss of $-40.3M to $51.0M over the same span. Per the market data, gross margin is 85.4%, operating margin 5.6%, and net margin 15.9%; the gap between operating and net margin is not explained in the source data. Per the RQD rating, ROIC is 6% and the Forensic Balance Sheet pillar cites Altman Z of 11.4 and Piotroski F of 7 of 9, with Debt/Equity at 0.5. Reported FCF declined from $91.1M in FY 2024 to $78.5M in FY 2025, and cash declined from $150.2M to $104.8M over the same period.
Per the recent news feed, the headlines cover the following themes:
Risk watch items: the feed contains no bearish headlines, and the YELLOW-flagged items are market-wire coverage without a stated directional signal. The Butterfly Supply-Chain Graph reports no proprietary signals and no links.
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Not available in source data: upstream suppliers, downstream customers, and sector correlation figures. Investors seeking second-order ripple analysis would need supplier and customer disclosures not present in this dataset.
Real-time company headlines, analyst actions, and sector developments for Inspire Medical Systems Inc. (INSP) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Inspire Medical Systems Inc. (INSP) market action, institutional positioning, and fundamental catalysts.
Welcome to the INSP (Inspire Medical Systems Inc.) Roar Pit. Current RQD Composite is 66/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on INSP, but look at what you are paying: 14.2x trailing P/E with 85.4% gross margins. Unless Inspire Medical Systems Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on INSP, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $71.18 (52-wk range $38.91 - $147.03), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).